Neuroblastoma, the third most common paediatric solid tumors afterleukaemiae and brain neoplasiae, with an incidence of approximately 1.3child out of 100.000, is responsible of 15% of all childhood cancer death.The acquisition of multidrug resistance upon treatment with anticancerdrugs is a common feature of highly malignant Neuroblastoma. Theidentification of marker proteins involved in chemo-resistance mightsignificantly help in the prognosis of this neoplasia by individualising thedrug treatment .Proteomics investigation might represent a powerful holistic scientificapproach in order to possibly characterised the molecular hallmarks ofNeuroblastoma chemoresistance. Combining high-resolution proteinseparations with mass spectrometry protein identification, proteomics allowsto explore the molecular mechanisms of cancer chemoresistance in a datadriven experimental design, therefore enabling the construction of novelhypothesis not necessarily linked to a define researcher theory.In the following we review the current state of the art in the proteomicsinvestigations devoted to the characterisation of Neuroblastoma drugresistance.
|Title of host publication||Neuroblastoma Research Trends|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||22|
|Publication status||Published - Apr 2008|
ASJC Scopus subject areas